Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, ct perfusion, tumor density, and tumor size (recist)

Investigative Radiology

Volumn 47, Issue 1, 2012, Pages 11-17

  Jiang, Tao ^a,b   Kambadakone, Avinash ^a   Kulkarni, Naveen M ^a   Zhu, Andrew X ^c   Sahani, Dushyant V ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

Antiangiogenic treatment; CT perfusion; Hepatocellular carcinoma; Image biomarker; RECIST

Indexed keywords

BEVACIZUMAB; GEMCITABINE; IOPAMIDOL; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ANTIANGIOGENIC THERAPY; ARTICLE; BLOOD VOLUME; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER REGRESSION; CANCER SIZE; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY PERFUSION IMAGING; CONTRAST ENHANCEMENT; DRUG MONITORING; DRUG RESPONSE; FEMALE; HUMAN; IMAGE ANALYSIS; IMAGE PROCESSING; LIVER CELL CARCINOMA; MALE; MULTIPLE CYCLE TREATMENT; ONCOLOGICAL PARAMETERS; OUTCOME ASSESSMENT; PERMEABILITY; PORTAL VEIN THROMBOSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURFACE PROPERTY; TUMOR BLOOD FLOW; TUMOR DENSITY; TUMOR THROMBUS;

EID: 84055167359     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e3182199bb5     Document Type: Article

References (37)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
2. Sahani DV, Holalkere NS, Mueller PR, et al. Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue-initial experience. Radiology. 2007;243:736-743.
3. Murukesh N, Dive C, Jayson GC. Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br J Cancer. 2010;102:8-18.
4. Willett CG, Duda DG, di Tomaso E, et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol. 2009;27:3020-3026.
5. Therasse P, Arbuck SG, Eisenhauer EA, et al. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205-216.
6. Nishino M, Jackman DM, Hatabu H, et al. New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy. Am J Roentgenol. 2010;195:W221-W228.
7. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1). Eur J Cancer. 2009;45:228-247.
8. Sahani DV, Kalva SP, Hamberg LM, et al. Assessing tumor perfusion and treatment response in rectal cancer with multisection CT: initial observations. Radiology. 2005;234:785-792.
9. Rosen M.A. Use of modified RECIST criteria to improve response assessment in targeted therapies: challenges and opportunities. Cancer Biol Ther. 2010;9:20-22.
10. Kan Z, Phongkitkarun S, Kobayashi S, et al. Functional CT for quantifying tumor perfusion in antiangiogenic therapy in a rat model. Radiology. 2005;237:151-158.
11. Marcus CD, Ladam-Marcus V, Cucu C, et al. Imaging techniques to evaluate the response to treatment in oncology: current standards and perspectives. Crit Rev Oncol Hematol. 2009;72:217-238.
12. Bruix J, Sherman M, Llovet JM, et al. European Association for the Study of the Liver. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J Hepatol. 2001;35:421-430.
13. Ungersma SE, Pacheco G, Ho C, et al. Vessel imaging with viable tumor analysis for quantification of tumor angiogenesis. Magn Reson Med. 2010; 63:1637-1647.
14. Ng CS, Wang X, Faria SC, et al. Perfusion CT in patients with metastatic renal cell carcinoma treated with interferon. Am J Roentgenol. 2010;194:166-171.
15. Kan Z, Kobayashi S, Phongkitkarun S, et al. Functional CT quantification of tumor perfusion after transhepatic arterial embolization in a rat model. Radiology. 2005;237:144-150.
16. Kambadakone AR, Sahani DV. Body perfusion CT: technique, clinical applications, and advances. Radiol Clin North Am. 2009;47:161-178.
17. Jiang HJ, Lu HB, Zhang ZR, et al. Experimental study on angiogenesis in a rabbit VX2 early liver tumour by perfusion computed tomography. J Int Med Res. 2010;38:929-939.
18. Goh V, Halligan S, Gharpuray A, et al. Quantitative assessment of colorectal cancer tumor vascular parameters by using perfusion CT: influence of tumor region of interest. Radiology. 2008;247:726-732.
19. Ng CS, Raunig DL, Jackson EF, et al. Reproducibility of perfusion parameters in dynamic contrast-enhanced MRI of lung and liver tumors: effect on estimates of patient sample size in clinical trials and on individual patient responses. Am J Roentgenol. 2010;194:W134-W140.
20. Zhu AX, Holalkere NS, Muzikansky A, et al. Early antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinoma. Oncologist. 2008;13:120-125.
21. Choi SH, Chung JW, Kim HC, et al. The role of perfusion CT as a follow-up modality after transcatheter arterial chemoembolization: an experimental study in a rabbit model. Invest Radiol. 2010;45:427-436.
22. Zhu AX, Blaszkowsky LS, Ryan DP, et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24:1898-1903.
23. Goetti R, Leschka S, Desbiolles L, et al. Quantitative computed tomography liver perfusion imaging using dynamic spiral scanning with variable pitch: feasibility and initial results in patients with cancer metastases. Invest Radiol. 2010;45:419-426.
24. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25:1753-1759.
25. Nishino M, Jagannathan JP, Ramaiya NH, et al. Revised RECIST guideline version 1.1: what oncologists want to know and what radiologists need to know. Am J Roentgenol. 2010;195:281-289.
26. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52-60.
27. Heiland S, Erb G, Ziegler S, et al. Where contrast agent concentration really matters-a comparison of CT and MRI. Invest Radiol. 2010;45:529-537.
28. Yang HF, Du Y, Ni JX, et al. Perfusion computed tomography evaluation of angiogenesis in liver cancer. Eur Radiol. 2010;20:1424-1430.
29. Goh V, Halligan S, Taylor SA, et al. Differentiation between diverticulitis and colorectal cancer: quantitative CT perfusion measurements versus morphologic criteria-initial experience. Radiology. 2007;242:456-462.
30. Sabir A, Schor-Bardach R, Wilcox CJ, et al. Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapy. Am J Roentgenol. 2008;191:133-139.
31. Park MS, Klotz E, Kim MJ, et al. Perfusion CT: noninvasive surrogate marker for stratification of pancreatic cancer response to concurrent chemo-and radiation therapy. Radiology. 2009;250:110-117.
32. Jiang T, Zheng X, Tao X, et al. How to choose PET-CT or CT in the diagnosis and staging of lung cancer. Practical experience in China. Nuklearmedizin. 2010;49:28-34.
33. Yamagami T, Arai Y, Takeuchi Y, et al. Increased hepatic arterial blood flow after decreased portal supply to the liver parenchyma owing to intrahepatic portosystemic venous shunt: angiographic demonstration using helical CT. Br J Radiol. 2000;73:1042-1045.
34. Cook KM, Figg WD. Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin. 2010;60:222-243.
35. Schramm P, Xyda A, Klotz E, et al. Dynamic CT perfusion imaging of intra-axial brain tumours: differentiation of high-grade gliomas from primary CNS lymphomas. Eur Radiol. 2010;20:2482-2490.
36. San Millan Ruiz D, Murphy K, Gailloud P. 320-multidetector row whole-head dynamic subtracted CT angiography and whole-brain CT perfusion before and after carotid artery stenting: technical note. Eur J Radiol. 2010;74:413-419.
37. Ganeshan B, Burnand K, Young R, et al. Dynamic contrast-enhanced texture analysis of the liver: initial assessment in colorectal cancer. Invest Radiol. 2011;46:160-168.